Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients (ECENVIR)
Asthma

About this trial
This is an interventional supportive care trial for Asthma focused on measuring Asthma, Medical Indoor Environment Counselors, Pediatric, Environment, Clinical effectiveness, Economical impact
Eligibility Criteria
Inclusion Criteria:
- age greater than or equal to 6 years and less than 45 (<45 years),
- patients with an eligible control level of asthma,
- sensitization to one or more allergens demonstrated during the last 36 months with prick tests (papules with a diameter > 3 mm compared to a negative control or > 50% of positive control) and/or specific IgE detection (> 0.10 U/mL),
- patients > 15 years presenting with a reversibility to ß2-agonists > 200 mL and/or > 12% compared to the initial FEV1 value (test performed at least once in life) or patients ≥ 6 years and ≤ 15 years presenting with a reversibility to ß2-agonists > 200 mL and/or > 12% compared to the initial FEV1 value (at least once in the life) and/or a positive metacholine challenge (at least once in the life),
- patients sleeping > 6 nights per week in the same house
- individuals affiliated to 1 of the 3 French social security (for matching data from French social security via SNIIRAM system),
- Only one patient per dwelling,
- Patient oral consent (written attestation by investigator)
Exclusion Criteria:
- chronic obstructive pulmonary disease (COPD),
- identified occupational asthma,
- Move within the 6 months before home intervention or predicted during the first year of inclusion,
- advices provided during the 2 years before inclusion during a home intervention of a MIEC
- active smokers or smoker who given up smoking less than 5 years ago, with a consumption of more than 10 years of 20 cigarettes/day, OR smoker who given up smoking more than 5 years ago, with a consumption of more than 20 years of 20 cigarettes/day,
- patients < 18 years for whom the parents (or legal guardian) are opposed to the inclusion in ECENVIR study,
- Major people being the object of a legal protection (protection(saving) of justice, guardianship, supervision(guardianship)) and private persons of freedom
Sites / Locations
- Strasbourg UH
- Aix-en-Provence Hospital
- Bordeaux University Hospital
- Caen University Hospital
- Chalon
- Chauny Hospital
- Dijon University Hospital
- Grenoble University Hospital
- Lille UH
- Macon Hospital
- Marseille European Hospital
- Marseille University Hospital
- Nantes University Hospital
- Reims University Hospital
- Rouen University Hospital
- Vire Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Other
Intervention group
Control group
Non intervention group
After randomisation and agreement of the patient and the family, the " intervention group " will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months.
The " control group " is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study. This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed.
The " non intervention " group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study.